Slingshot members are tracking this event:
Allergan (AGN) recieves FDA Acceptable for Filing Letter for Generic XIFAXAN® ANDA
Do you think this event is important to the companies below? How will it affect their stock price?
Based on available information, Allergan believes it is the "first applicant" to file an ANDA for the generic version of XIFAXAN® 550 mg and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity.
Slingshot Insights Explained
Feb 29, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Abbreviated New Drug Application, Rifaximin, Irritable Bowel Syndrome, Generic Drug, Fda Approval, Hepatic Encephalopathy